IMVARIA is a clinical AI company generating novel physiologic signatures from clinical testing and imaging. Serving Fibresolve and ScreenDx — the first FDA-authorized AI diagnostic tools in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD).

IMVARIA serves Fibresolve -- the first AI diagnostic tool in interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Fibresolve is an FDA Breakthrough Device and is authorized by the FDA to serve as an adjunctive, non-invasive diagnostic tool for patients with suspected ILD and IPF.



Beyond ILD and IPF, IMVARIA is developing AI biomarkers in multiple areas including oncology, pulmonology, immunology, and more.